Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LOS ANGELES, June 03, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), a biotechnology company developing potentially curative and preventative genetically modified cellular and...
-
LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), et bioteknologiselskab, der udvikler potentielt helbredende og forebyggende, genetisk modificerede...
-
Enochian developing ENOB-HV-01 an autologous cell therapy as a potentially curative treatment for HIV LOS ANGELES, March 07, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), a...
-
LOS ANGELES, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) a biopharmaceutical company focused on the development and commercialization of novel therapies for HIV/AIDS...
-
– Appoints former President of GSK Global Vaccine business, Luc Debruyne, to Board of Directors – – Advances ENO-1001 for HIV by entering into research collaboration with Scripps Research –...
-
LOS ANGELES, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB: ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell...
-
LOS ANGELES, July 20, 2018 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB:ENOB), a biopharmaceutical company focused on the development and commercialization of novel therapies...